caffeine has been researched along with edaravone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
Bandookwala, M; Khairnar, A; Sahu, AK; Sengupta, P; Sharma, M; Thakkar, D | 1 |
2 other study(ies) available for caffeine and edaravone
Article | Year |
---|---|
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Caffeine; Drug Synergism; Edaravone; Lipid Peroxidation; Male; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Uncoupling Agents | 2019 |